XENE | tickerfilter.com

Fundamental analysis

16%

Profitability 25%

Dept financing 5%

Liquidity 50%

Performance 2%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

1.18%

1 Month

6.59%

3 Months

-4.35%

6 Months

9.79%

1 Year

15.82%

2 Year

-6.41%

Key data

Stock price

$42.05

P/E Ratio

0.00

DAY RANGE

$41.83 - $43.68

EPS

-$4.36

52 WEEK RANGE

$26.74 - $46.99

52 WEEK CHANGE

$15.48

MARKET CAP

3.463 B

YIELD

N/A

SHARES OUTSTANDING

83.190 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-07-2025

BETA

1.13

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,094,944

AVERAGE 30 VOLUME

$896,860

Company detail

CEO: Ian C. Mortimer
Region: US
Website: xenon-pharma.com
Employees: 210
IPO year: 2014

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Xenon Pharmaceuticals Inc. engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy. XEN007, a central nervous system-acting calcium channel modulator, is in Phase II clinical trials.

XENE - Xenon Pharmaceuticals Inc.